Severe digital ischemia, including digital ulcers and gangrene, is considered rare in patients with antisynthetase antibodies. This study aimed to elucidate the clinical features of antisynthetase-positive patients complicated with digital ulcers and/or gangrene using a systematic literature review and case series in a single-center cohort.
Methods:
A systematic literature review was conducted to identify reports describing antisynthetase-positive cases with digital ulcers and/or gangrene. Our cohort of consecutive patients with antisynthetase antibodies was stratified by the history of severe digital ischemia. Demographic and clinical features and outcomes in patients with severe digital ischemia identified in the systematic literature review and our cohort were compared with those in patients without severe digital ischemia in our cohort.
Results:
The systematic literature review revealed 12 antisynthetase-positive patients with severe digital ischemia from one case series and eight case reports. Seven (7%) of 100 patients with antisynthetase antibodies in our cohort had a record of severe digital ischemia. Severe digital ischemia was often found at presentation and was associated with the classification of systemic sclerosis with or without myositis overlap. Clinical features associated with severe digital ischemia in antisynthetase-positive patients included Raynaud’s phenomenon (p < 0.001), digital pitting scars (p = 0.001), and nailfold capillary abnormality (p = 0.02). Outcomes of severe digital ischemia were generally favorable with vasodilators.
Conclusion:
Severe digital ischemia is an overlooked complication in antisynthetase-positive patients. Antisynthetase antibodies should be measured in patients presenting with digital ulcers or gangrene, especially in those with systemic sclerosis phenotype and features associated with antisynthetase antibodies in the absence of systemic sclerosis-specific autoantibodies.
GonoTKuwanaM.Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. Expert Rev Clin Immunol2020; 16(1): 79–89.
2.
McHughNJTansleySL.Autoantibodies in myositis. Nat Rev Rheumatol2018; 14: 290–302.
3.
FischerAAntoniouKMBrownKK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J2015; 46(4): 976–987.
MarcoJLCollinsBF.Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol2020; 34(4): 101503.
6.
OpincAHMakowskaJS.Antisynthetase syndrome—much more than just a myopathy. Semin Arthritis Rheum2021; 51(1): 72–83.
7.
Mescam-ManciniLAllenbachYHervierB, et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain2015; 138(Pt 9): 2485–2492.
8.
UruhaASuzukiSSuzukiN, et al. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain2016; 139: e50.
9.
WasedaYJohkohTEgashiraR, et al. Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol2016; 85(8): 1421–1426.
10.
CavagnaLTrallero-AraguásEMeloniF, et al. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course. J Clin Med2019; 8: 2013.
11.
LillekerJBVencovskyJWangG, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis2018; 77(1): 30–39.
12.
SebastianiMTriantafylliasKManfrediA, et al. Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations: results of a multicenter international study. J Rheumatol2019; 46(3): 279–284.
13.
FukueRGonoTHayashiH, et al. Rapidly progressive multiple digital gangrene and diffuse alveolar damage in a patient with antisynthetase antibody and gastric cancer. J Clin Rheumatol2018; 27: S585–S589.
14.
StewartLAClarkeMRoversM, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA2015; 313: 1657–1665.
15.
WellsGO’ConnellDPetersonJ, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2013, accessed 21 November 2021).
16.
HamaguchiYFujimotoMMatsushitaT, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE2013; 8(4): e60442.
17.
MathewsMBBernsteinRM.Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature1983; 304: 177–179.
18.
MathewsMBReichlinMHughesGR, et al. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med1984; 160: 420–434.
19.
BunnCCBernsteinRMMathewsMB.Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med1986; 163: 1281–1291.
20.
TargoffIN.Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol1990; 144: 1737–1743.
21.
HirakataMSuwaANagaiS, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol1999; 162: 2315–2320.
22.
KuwanaM.Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting. J Nippon Med Sch2017; 84(2): 56–63.
23.
SatoSHoshinoKSatohT, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum2009; 60(7): 2193–2200.
24.
LundbergIETjärnlundABottaiM, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis2017; 76: 1955–1964.
25.
van den HoogenFKhannaDFransenJ, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum2013; 65: 2737–2747.
26.
KanekoYHanaokaHHirakataM, et al. Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology (Oxford)2014; 53(6): 1120–1124.
27.
SulliASecchiMEPizzorniC, et al. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis2008; 67(6): 885–887.
28.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med2002; 165: 277–304.
29.
DurackDTStreetAC.Fever of unknown origin—reexamined and redefined. Curr Clin Top Infect Dis1991; 11: 35–51.
30.
IsenbergDAAllenEFarewellV, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Rheumatology (Oxford)2004; 43(1): 49–54.
31.
KhannaDFurstDEClementsPJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord2017; 2(1): 11–18.
32.
LightfootRWJrMichelBABlochDA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum1990; 33: 1088–1093.
33.
SulimanYABruniCJohnsonSR, et al. Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) definition. J Scleroderma Relat Disord2017; 2(2): 115–120.
34.
AmanziLBraschiFFioriG, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford)2010; 49(7): 1374–1382.
35.
KandaY.Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant2013; 48(3): 452–458.
36.
ThoelkeASchmidHPFiglR, et al. Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma. Eur J Dermatol2006; 16(4): 428–430.
37.
LaugharneMWoodJMitchellD, et al. Arterial occlusion from anti-jo1 antibody-associated autoimmune myositis: arteritis not compartment syndrome. EJVES Extra2007; 13: 23–25.
38.
HervierBLambertMHachullaE, et al. Anti-synthetase syndrome positive for anti-isoleucyl-tRNA synthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjogren’s syndrome. Rheumatology (Oxford)2011; 50(6): 1175–1176.
39.
RanaJMoyAPPirisA, et al. Lupus and scleroderma overlap features in a 28-year-old man with anti-PL-12 anti-synthetase syndrome. Dermatol Online J2017; 23: 13030.
40.
ChanJEPalakodetiSKosterMJ.Acute digital ischemia: a rare presentation of antisynthetase syndrome. Eur J Rheumatol2017; 4(1): 63–65.
MiyagawaFAzukizawaHMimoriT, et al. Anti-PL-12 antibody-positive antisynthetase syndrome with recurrent digital ulcers. J Dermatol2019; 46(4): e143–e145.
43.
SumaHYoshidaYSugimotoT, et al. The clinical characteristics and predictors of severe digital ischemia in patients with anti-aminoacyl transfer RNA synthetase antibodies. J Dermatol2021; 48(7): 1044–1051.
44.
YehudinaYTrypilkaSIsayevaA.Clinical puzzles and decision-making in antisynthetase syndrome. Cureus2021; 13: e15931.
45.
HughesMHerrickAL.Digital ulcers in systemic sclerosis. Rheumatology (Oxford)2017; 56: 14–25.
46.
NakashimaRImuraYHosonoY, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS ONE2014; 9(1): e85062.
47.
HanaokaHKanekoYSuzukiS, et al. Anti-signal recognition particle antibody in patients without inflammatory myopathy: a survey of 6180 patients with connective tissue diseases. Scand J Rheumatol2016; 45(1): 36–40.
48.
PaulingJDSalazarGLuH, et al. Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatology (Oxford)2018; 57: 712–717.
49.
MinierTGuiducciSBellando-RandoneS, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis2014; 73(12): 2087–2093.
50.
Muñoz-BeamudFIsenbergDA.Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol2013; 31(6): 896–903.
51.
GonoTKanekoHKawaguchiY, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford)2014; 53: 2196–2203.
52.
JohnsonDvan EedenCMoazabN, et al. Nailfold capillaroscopy abnormalities correlate with disease activity in adult dermatomyositis. Front Med (Lausanne)2021; 8: 708432.
53.
DanieliMGVergaJUMezzanotteC, et al. Replacement and immunomodulatory activities of 20% subcutaneous immunoglobulin treatment: a single-center retrospective study in autoimmune myositis and CVID patients. Front Immunol2022; 12: 805705.
54.
FrerixMStegbauerJDragunD, et al. Ulnar artery occlusion is predictive of digital ulcers in SSc: a duplex sonography study. Rheumatology (Oxford)2012; 51(4): 735–742.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
